600420.SHG Shanghai Shyndec Pharmaceutical Co Ltd
- Market cap
- CNY 11.2B
- P/E
- 24.6x
- P/B
- 0.81x
- ROE
- 3.0%
- Dividend yield
- 3.82%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600420.SHG undervalued?
Graham number600420.SHG trades 5.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Shyndec Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Shanghai Shyndec Pharmaceutical Co Ltd yet.
Shanghai Shyndec Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Shyndec Pharmaceutical Co Ltd
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company provides nifedipine controlled release tablets, penicillin industrial potassium salt, touboke yuekui granules/capsules, sodium cefuroxime for injection, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, and cefoperazone dispersible tablets; and cefuroxime axetil tablets, cefuroxime sod…
Full company profileShanghai Shyndec Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Shyndec Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 9.13B | 8.52B | 11.3B | 12.2B | 12.6B | 13.9B | 13.0B | 12.1B | 10.9B | 9.36B | 7.45B |
| Gross Profit | 3.21B | 3.63B | 5.46B | 5.96B | 5.79B | 6.04B | 4.87B | 4.53B | 4.12B | 9.36B | 2.17B |
| Operating Income | 898M | 923M | 1.28B | 1.03B | 1.02B | 898M | 966M | 1.08B | 1.75B | 1.31B | 699M |
| EBITDA | 2.07B | 2.03B | 2.24B | 1.99B | 1.90B | 1.81B | 1.93B | 1.98B | 2.46B | 2.08B | 700M |
| Net Income | 477M | 516M | 706M | 656M | 649M | 568M | 628M | 692M | 1.08B | 944M | 415M |
| EPS | 0.43 | 0.46 | 0.65 | 0.57 | 0.55 | 0.48 | 0.54 | 0.54 | 0.81 | 0.70 | 0.31 |
| Balance Sheet | |||||||||||
| Total Assets | 15.0B | 15.2B | 16.5B | 17.6B | 18.3B | 19.1B | 19.6B | 19.4B | 20.0B | 19.2B | 19.4B |
| Total Liabilities | 8.08B | 7.52B | 8.02B | 8.44B | 8.43B | 8.70B | 7.48B | 5.01B | 4.63B | -15.7B | 3.45B |
| Shareholders' Equity | 5.70B | 6.17B | 6.81B | 7.59B | 8.13B | 8.59B | 10.3B | 12.4B | 13.2B | 15.7B | 13.8B |
| Cash & Short-term Investments | 1.64B | 2.44B | 3.83B | 5.16B | 3.72B | 4.28B | 6.15B | 5.97B | 7.64B | 4.14B | 4.14B |
| Total Debt | 4.94B | 4.10B | 3.73B | 4.30B | 3.15B | 3.58B | 3.40B | 1.13B | 1.74B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 839M | 2.31B | 1.67B | 1.27B | 1.56B | 1.68B | 2.86B | 1.72B | 2.26B | 1.70B | - |
| Capital Expenditure | 241M | 168M | 399M | 404M | 378M | 521M | 307M | 357M | 220M | 264M | 192M |
| Free Cash Flow | 597M | 2.15B | 1.27B | 866M | 1.18B | 1.16B | 2.55B | 1.36B | 2.04B | 1.43B | -102M |
| Ratios | |||||||||||
| ROE | 8.4% | 8.4% | 10.4% | 8.7% | 8.0% | 6.6% | 6.1% | 5.6% | 8.2% | 6.0% | 3.0% |
| ROA | 3.2% | 3.4% | 4.3% | 3.7% | 3.6% | 3.0% | 3.2% | 3.6% | 5.4% | 4.9% | 2.1% |
| Net Profit Margin | 5.2% | 6.1% | 6.2% | 5.4% | 5.2% | 4.1% | 4.8% | 5.7% | 9.9% | 10.1% | 5.6% |
| Debt to Equity | 0.87x | 0.66x | 0.55x | 0.57x | 0.39x | 0.42x | 0.33x | 0.09x | 0.13x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai Shyndec Pharmaceutical Co Ltd dividends
- Dividend yield
- 3.82%
- Forward dividend
- 0.25 CNY
- Payout ratio
- 45.3%
- Ex-dividend date
- Sep 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 428M | 0.32 | 45.3% |
| 2024 | CNY 301M | 0.22 | 27.7% |
| 2023 | CNY 189M | 0.15 | 27.4% |
| 2022 | CNY 103M | 0.09 | 16.4% |
| 2021 | CNY 212M | 0.18 | 37.4% |
| 2020 | CNY 103M | 0.09 | 15.8% |
| 2019 | CNY 106M | 0.09 | 16.1% |
| 2018 | CNY 457M | 0.42 | 64.8% |
| 2017 | CNY 396M | 0.36 | 76.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on May 25, 2017.
Who owns Shanghai Shyndec Pharmaceutical Co Ltd
- Insiders 63.24%
- Institutions 0.76%
- Public & others 36.00%
- Shares outstanding 1.34B
- Free float 544M
Shanghai Shyndec Pharmaceutical Co Ltd company profile
- Company name
- Shanghai Shyndec Pharmaceutical Co Ltd
- Ticker
- 600420.SHG
- ISIN
- CNE000001JG2
- Exchange
- Shanghai Stock Exchange
- Listed since
- Jun 1, 2004
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 9,697
- Fiscal year end
- December
- Address
- No. 378, Jianlu Road, Shanghai, China, 200137
- Phone
- 86 21 6251 0990
- Website
- shyndec.com
About Shanghai Shyndec Pharmaceutical Co Ltd
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company provides nifedipine controlled release tablets, penicillin industrial potassium salt, touboke yuekui granules/capsules, sodium cefuroxime for injection, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, and cefoperazone dispersible tablets; and cefuroxime axetil tablets, cefuroxime sodium for injection, cefaclor extended-release capsules, cefixime granules, and cefdinir dispersible tablets. It also offers nifedipine controlled-release tablets, amlodipine besylate tablets, enalapril maleate tablet, pravastatin sodium tablets, olmesartan medoxomil hydrochlorothiazide tablets, olmesartan amlodipine tablets; milnaprom hydrochloride tablets, lofen codeine tablets, gastrodin injection, naloxone hydrochloride injection, piracetam injection; and apmis film, tacrolimus capsules, mannan peptide for injection, imatinib mesylate. In addition, the company provides methylprednisolone sodium succinate for injection, octreotide acetate injection, betamethasone sodium phosphate for injection, dexamethasone sodium phosphate injection; diclofenac sodium sustained release tablets; 6-aminopenicillinic acid, azithromycin, amoxicillin, potassium clavulanate microcrystalline cellulose, ceftriaxone sodium crude salt, 7-aminocephalosporanic acid, chorionic gonadotropin, urinary gonadotropin; and naphazoline hydrochloride nasal drops, Ambroxol Hydrochloride Oral Solution. Shanghai Shyndec Pharmaceutical Co., Ltd. was founded in 1996 and is based in Shanghai, China.
Shanghai Shyndec Pharmaceutical Co Ltd management
5- Mr. Yong LiuPresident & Director · born 1969
- Mr. Xiangchen WangChief Financial Officer · born 1972
- Mr. Zhongxi ZhangVP, General Counsel, Chief Compliance Officer & Board Secretary · born 1976
- Cai Zheng yanVice President
- Lei GaoAccounting Supervisor